Table 6.
Studies reported VCF after SBRT for spinal metastases
| References | Patients (Lesions) | Tumor type | Dose (Gy)/Fraction | Follow‐up (mo, median) | VCF | Time to VCF (mo) |
|---|---|---|---|---|---|---|
| Virk et al12 | 323 (552) | mixed | 24/1 | 12.6 | 7.2% (5‐y) | 13 |
| Ghia et al15 | NA (13) | mixed | 24/1 | 23 | 46.2% | NA |
| Garg et al22 | 61 (63) | mixed | 16‐24/1 | 19.7 (mean) | 21.3% | NA |
| Bate et al23 | NA (38) | mixed | 16‐23/1 | 10 | 2.6% | NA |
| Hashmi et al24 | 215 (247) | mixed | 18/1 | 8.1 | 4.5% | NA |
| Miller et al26 | 38 (56) | MM | 16/1 | 26 | 21% | NA |
| Miller et al27 | 249 (NA) | mixed | 16/1 | 18 and 12a | 18.9% | NA |
| Zeng et al29 | 52 (93) | mixed | 24/2 | 14.4 and 19.5b | 3.8% | NA |
| Tseng et al32 | 145 (279) | mixed | 24/2 | 15 | 13.8% (2‐y) | NA |
| Ito et al30 | 131 (134) | mixed | 24/2 | 9 | 11.9% | NA |
| Ito et al31 | 28 (28) | mixed | 24/2 | 13 | 10.7% | NA |
| Chang et al33 | 60 (72) | mixed | 24/2 | 21 | 6.7% | 15.4 |
| Thibault et al34 | NA (61) | RCC | 24/2 | 12.3 | 16% | NA |
| Bate et al23 | NA (31) | mixed | 20‐30/2‐5 | 10 | 12.9% | NA |
| Ghia et al15 | NA (11) | mixed | 27/3 and 30/5 | 23 | 9.1% | NA |
| Silva et al38 | 61 (72) | mixed | 27/3 and 35/5 | 13.58 | 20.8% | NA |
| Park et al39 | 39 (59) | mixed | 27/3 | 7.4 | 5.1% | 1.2 and 1.4c |
| Guckenberger et al43 | 301 (387) | mixed | 24/3 | 11.8 | 7.8% | 11.5 |
| Mehta et al41 | 83 (98) | mixed | 24/3 | 7.6 | 4.2% | 5.8 |
| Kim et al44 | 22 (31) | mixed | 24/3 | 10 | 19.4% | NA |
| Puvanesarajah et al47 | 99 (NA) | mixed | 21/3 | 6.1 | 7.0% | 3.3 |
| Sohn et al8 | 13 (NA) | RCC | 38d/4 | NA | 15.4% | NA |
Abbreviations: Gy: gray; MM: multiple myeloma; mo: month; NA: not applied; VCF: vertebral compression fractures; y: year.
a
Median follow‐up for instrumentation cohort and control cohort.
b
Median follow‐up for cervical cohort and sacral cohort.
c
Time to VCF for two patients.
d
Mean total margin radiation dose.